[paper](https://spectrumhealth-my.sharepoint.com/:w:/r/personal/weili_zheng_corewellhealth_org/_layouts/15/Doc.aspx?sourcedoc=%7B01FBC96D-2E0B-4466-81CD-775CF69C81DE%7D&file=Implant_May10_2022.docx&action=default&mobileredirect=true)
[figures](https://spectrumhealth-my.sharepoint.com/:w:/r/personal/weili_zheng_corewellhealth_org/_layouts/15/Doc.aspx?sourcedoc=%7B7631DBD9-B153-4031-89EF-1C44CB011A99%7D&file=Figures_May10_2022.docx&action=default&mobileredirect=true)
[tables](https://spectrumhealth-my.sharepoint.com/:w:/r/personal/weili_zheng_corewellhealth_org/_layouts/15/Doc.aspx?sourcedoc=%7BCBFB4BDA-DE15-45FB-9DC2-D2D62421ED1E%7D&file=Tables_May10_2022.docx&action=default&mobileredirect=true)

# Notes/ideas
- more evidence for beam angle effects
- with SPArc, can situate tumor in the 80% SOBP location where perturbation is more certain and avoid uncertainties associated with the distal beam edge in close proximity to the
- 10% dose perturbation threshold (44, 19-22). We use 5% dose perturbation and 1% range difference (10%, 2% = acceptable)
- SPArc likely would perform better with unknown material composition where the dose errors from insufficient scatter modelling is spread out amongst many many angles. 